Back to Journals

OncoTargets and Therapy


Aims and Scope

Editor-in-Chief: Dr Faris Farassati

 

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.  

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. 

Specific topics covered by the journal include: 

  • Novel therapeutic targets and innovative agents
  • Novel therapeutic regimens for improved benefit and/or decreased side effects
  • Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy: 

  • Studies containing in vivo animal model data will be considered favorably. 
  • Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. 
  • Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. 
  • Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. 
  • Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. 
  • Single nucleotide polymorphism (SNP) studies will not be considered.

Case reports and protocols will be considered if focused on molecular pathology and make a valuable and original contribution to the literature. 

As of 18th March 2019, OncoTargets and Therapy will no longer consider meta-analyses for publication.